A quiet but consequential bet is being placed on African biotech. Reme-D, a diagnostics-focused startup, has closed a $1.45 million funding round aimed at scaling local manufacturing of diagnostic tools — a sector that has long been dominated by imports, according to Tech Build Africa.

The raise is modest by global standards, but context matters. Africa's diagnostics market has historically relied on equipment and test kits manufactured abroad — a vulnerability that the COVID-19 pandemic exposed with brutal clarity when supply chains seized up and testing capacity collapsed across the continent. Reme-D is positioning itself as part of the structural fix.

Local manufacturing of diagnostics is not just a public health argument — it is an economic one. When a hospital in Nairobi or Lagos procures test kits made in Africa, the value stays on the continent: jobs, IP, supply chain resilience. Investors appear to be waking up to this logic, with biotech increasingly appearing alongside fintech and agritech as a category worth backing in African venture portfolios.

The $1.45 million, while early-stage, gives Reme-D the runway to develop or expand its manufacturing capabilities and potentially begin moving products through procurement channels — both private healthcare networks and public health systems, which remain the largest buyers of diagnostics across the continent.

For operators watching this space, the signal is clear: the narrative around African healthtech is shifting. It is no longer only about last-mile delivery apps or telemedicine platforms. Deep biotech — manufacturing, reagents, diagnostics — is beginning to attract capital, even if the cheque sizes are still relatively small compared to the sector's capital requirements.

The road ahead for Reme-D will not be simple. Regulatory approval across multiple African markets, quality certification, and building trust with procurement officers trained to default to established international brands are all real hurdles. But the funding suggests investors believe the opportunity — and the team — are worth the risk.

Why it matters: As African governments push for self-sufficiency in healthcare supply chains post-pandemic, startups like Reme-D that bet on local diagnostic manufacturing could become critical infrastructure — and early investors are starting to price in that possibility.